细胞减灭术和 HIPEC 治疗恶性腹膜间皮瘤：来自澳大利亚中心的结果和生存情况。
Cytoreductive Surgery and HIPEC for Malignant Peritoneal Mesothelioma: Outcomes and Survival From an Australian Centre.
机构信息
Hepatobilliary and Surgical Oncology Unit, Department of Surgery, St. George Hospital, Kogarah, NSW, Australia.
School of Medicine, University of Notre Dame, Sydney, NSW, Australia.
出版信息
Anticancer Res. 2022 Jun;42(6):2939-2944. doi: 10.21873/anticanres.15776.
BACKGROUND/AIM: The aim of the study was to determine outcomes and overall survival (OS) in patients undergoing cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) for malignant peritoneal mesothelioma (MPM).
PATIENTS AND METHODS
This was a retrospective cohort study from a prospectively maintained database of patients that underwent CRS/HIPEC for MPM from April 1999 to December 2021.
RESULTS
A total of 81 patients were identified with MPM. Median OS was 53 months with a 1-, 3- and 5-year OS of 76%, 55% and 49% respectively. Multivariate analysis identified lymph node status, PCI and CC score as statistically significant prognostic factors that impact survival. Median OS for PCI 0-20 was 103 months vs. 33 months for PCI 21-39 (p=0.005). Median OS for CC0, CC1 and CC2 were 104, 30 and 2.7 months respectively (p<0.001). Hazard ratio for node-positive disease over node-negative was 2.14 (95% CI=1.07-4.31, p<0.033). Grade III/IV complication rate was 43.2% and mortality 4.9%.
CONCLUSION
CRS/HIPEC remains the gold standard for treating patients with MPM with excellent patient OS. Lymph node status, PCI and CC score were independent prognostic factors that affect OS.
背景/目的：本研究旨在确定接受细胞减灭术（CRS）和腹腔内热化疗（HIPEC）治疗恶性腹膜间皮瘤（MPM）患者的治疗效果和总生存期（OS）。
患者和方法
这是一项回顾性队列研究，来自 1999 年 4 月至 2021 年 12 月期间接受 CRS/HIPEC 治疗 MPM 的前瞻性维护数据库。
结果
共确定了 81 名患有 MPM 的患者。中位 OS 为 53 个月，1 年、3 年和 5 年的 OS 分别为 76%、55%和 49%。多变量分析确定了淋巴结状态、PCI 和 CC 评分是影响生存的统计学显著预后因素。PCI 0-20 的中位 OS 为 103 个月，而 PCI 21-39 的中位 OS 为 33 个月（p=0.005）。CC0、CC1 和 CC2 的中位 OS 分别为 104、30 和 2.7 个月（p<0.001）。阳性淋巴结疾病的风险比为 2.14（95%CI=1.07-4.31，p<0.033）。III/IV 级并发症发生率为 43.2%，死亡率为 4.9%。
结论
CRS/HIPEC 仍然是治疗 MPM 患者的金标准，患者的 OS 非常好。淋巴结状态、PCI 和 CC 评分是影响 OS 的独立预后因素。
Zotero 插件